BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Core Insights - BriaCell Therapeutics Corp. has received a research grant of $2,054,651 from the National Cancer Institute to advance its Bria-PROS+ immunotherapy for prostate cancer [1][7] - The grant will support the completion of manufacturing for Bria-PROS+ and fund a Phase 1/2a clinical trial in patients with advanced prostate cancer [2][7] - The Bria-OTS+ platform aims to simplify and expedite personalized cancer treatments, addressing significant unmet medical needs in cancer care [4][7] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [4] - The company is advancing its Bria-PROS+ platform, which is designed to provide off-the-shelf personalized immunotherapy solutions [4][7] Clinical Development - The upcoming Phase 1/2a clinical trial will investigate the efficacy of Bria-PROS+ in patients with metastatic prostate cancer, a condition with limited treatment options [3][7] - Dr. William Oh from Yale Cancer Center is the Principal Investigator for the clinical study, highlighting the urgency of addressing unmet medical needs in this area [3][7]